AI4LUNGS

AI4LUNGS is an innovative project funded by the European Union under the Horizon Europe Programme, aimed at transforming the diagnosis and treatment of lung diseases through advanced artificial intelligence (AI) technologies. The project introduces two groundbreaking technologies: digital auscultation and early-stage liquid biopsy. Digital auscultation enhances the traditional method of listening to lung sounds, while early-stage liquid biopsy aims to identify cancer types more efficiently, reducing unnecessary examinations and speeding up the diagnosis process, thereby cutting costs.

AI4LUNGS serves healthcare providers, particularly doctors specializing in respiratory diseases, by offering tools that personalize treatment and improve diagnostic accuracy. The project operates in the healthcare market, focusing on respiratory diseases, and leverages a business model centered around the development and deployment of AI-driven decision support systems. Revenue is generated through grants, partnerships, and potentially through the commercialization of its technologies.

The project also aims to develop a virtual digital twin, which will serve as an interface showcasing patient history, current status, and the performance of various AI models developed within the project. This digital twin will provide a comprehensive view of the patient's condition, aiding in more informed healthcare decisions.

AI4LUNGS aims to scale its technologies for broader use across different healthcare settings and diseases, promoting more sustainable healthcare and better resource allocation. The project's success will not only benefit health systems but also have a positive economic impact by reducing healthcare costs associated with respiratory diseases.

Keywords: AI, lung diseases, digital auscultation, liquid biopsy, diagnosis, healthcare, personalized treatment, virtual digital twin, sustainable healthcare, cost reduction.